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Background: We aimed to calculate the responsiveness and statistically prove the reliability of the Medical
Outcomes Study Short Form Health Survey (SF-36) in a prospective cohort study. We investigated the profile of
mid-term health-related quality of life (QOL) outcome assessments after surgery for cervical spondylotic myelopathy
(CSM) and determined the consistency of the SF-36 assessments of neurological function.
Methods: A total of 142 consecutive patients with CSM who underwent surgery were enrolled in the study.
QOL and neurological assessments were evaluated before and at 3 months, 1 year, and more than 2 years
postoperatively. We subsequently analyzed the reliability and responsiveness of the SF-36 and the QOL profile
for its consistency regarding the neurological function assessment.
Results: (1) Cronbach’s α ranged from 0.73 (for role-emotional) to 0.85 (for physical function). The effect size
ranged from 0.57 to 0.93 for SF-36’s eight scales. Minimum clinically important differences (MCIDs) in the physical
scores (PCS) and mental scores (MCS) were 5.52 and 3.43, respectively. (2) The scores for all SF-36 scale sections
indicated that patients with CSM were significantly impaired compared with healthy adults. SF-36 PCS and MCS
peaked at 17.7 and 18.9 months after surgery, respectively. (3) At 3 months after surgery, improvements in the
modified Japanese Orthopaedic Association (mJOA) scores significantly correlated only with patients’ physical
function and bodily pain scores. At 1 year after surgery, improvements in the mJOA scores significantly correlated
with physical function, general health, social function, and role-emotional. At the final follow-up, improvements
in the mJOA scores significantly correlated with physical function, vitality, and role-emotional.
Conclusions: SF-36 is reliable and has moderate responsiveness for evaluating patients with CSM, with MCID at
5.52 for the PCS and at 3.43 for the MCS. The preoperative QOL of the CSM patients was severely impaired
compared with that of the normal population. Postoperatively, each SF-36 domain improved to a variable degree.
During the early stage of recovery the mJOA score improvements correlated with SF-36’s physical component
domains, whereas during the later stages the improvements were associated with the mental component domains.
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The Medical Outcomes Study Short Form Health Survey
(SF-36) is a health status questionnaire that was devel-
oped approximately two decades ago to assess functional
status and well-being [1]. The SF-36 has been applied in
a variety of clinical settings, including orthopedic sur-
gery, for which it has frequently been used to evaluate
the psychometric and clinimetric properties of other
self-report questionnaires [2-6].
Cervical spondylotic myelopathy (CSM) is one of the
most prevalent and increasingly observed neurological
disorders in the geriatric population, and surgical man-
agement has been considered the most effective
treatment approach [7,8]. The time required to attain
maximum recovery after surgery is one of the greatest
concerns of both physicians and patients. Little rele-
vant information, however, has been reported on the
subject. To date, few studies have focused on SF-36
scores after surgery for CSM patients or on their
consistency with neurological function assessments. To
fill this void, we designed the current study to involve
the collection of prospective patient data and the retro-
spective analysis of follow-up data obtained from 142
patients with CSM who underwent surgical treatment.
We then calculated the responsiveness and statistically
demonstrated the reliability of the SF-36 in a cohort of
Chinese patients. We subsequently explored the pro-
files of mid-term health-related quality of life (QOL)
outcome assessments after surgery for these CSM pa-
tients and their consistency with neurological function
assessments using a prospective cohort study.Methods
Study design and population
We prospectively collected data for 142 CSM patients
who were admitted and treated at our institution
from February 2008 to November 2011.We used the
modified Japanese Orthopaedic Association (mJOA)
assessment and the SF-36 to evaluate the patients pre-
operatively and again at follow-up visits at 3 months,
1 year, and more than 2 years after their surgery. The
patients were diagnosed with CSM based on their dis-
ease history, physical examination, imaging studies,
and having undergone ineffective conservative treat-
ment. Patients who experienced trauma during the
same period or who had had poorly controlled disor-
ders preoperatively (e.g., serious systemic infection,
coronary heart disease, diabetes) were not included in
this study. The same group of surgeons in our hospital
treated the enrolled patients. We then analyzed the
reliability and responsiveness of the SF-36 and QOL
profile, and their consistency with neurological function
assessments.Treatment efficacy evaluation methods
The patients completed all of the evaluations under the
guidance of specially trained medical personnel. All follow-
up evaluations were performed at an outpatient clinic.
 mJOA assessment: This evaluation method, released
by the Japanese Orthopaedic Association (JOA) on
March 18, 1994, after several amendments, is used to
evaluate spinal cord function of patients with CSM.
The scores range from 0 to 17. The items evaluated
are upper and lower extremity motor functions,
sensory disturbances, and bladder function [9].
 Health measurement scale (SF-36): The SF-36 is a
concise health measurement scale that was developed
by the American Institute of Health (in Boston, MA).
From a quantitative perspective, this scale provides
a more intuitive and comprehensive reflection of
the health status of a population. The scale covers
eight aspects of health-related QOL: physical function
(PF), role-physical (RP), bodily pain (BP), general
health (GH), vitality (VT), social function (SF),
role-emotional (RE), and mental health (MH). For
comparison, these eight sections can be categorized
into two areas: SF-36 physical scores (PCS) and
SF-36 mental scores (MCS). The health transition
item (HTI), derived from the HTI of the SF-36,
refers to how the patient feels at the time of the
questionnaire compared with 1 year prior [10].
 Peak recovery time: This measure was determined
as the time point at which maximum recovery was
obtained. It was evaluated for each patient. When
the curve of the patient’s scores displayed double
peaks, the earlier time point was considered the
peak time.
Statistical analysis
The SPSS 13.0 statistical package (SPSS, Chicago, IL)
was used to establish a database and perform data man-
agement and analysis. The means and standard devia-
tions (SDs) were computed for continuous variables.
The analysis methods included descriptive statistics and
numerical data. The prevalences of the lowest scores, 0/
100 (floor effect), and highest scores, 100/100 (ceiling
effect), for the PCS and MCS of the SF-36 were calcu-
lated. Intergroup comparisons were conducted using the
Mann–Whitney U-test. Correlation analyses were per-
formed using Spearman’s rank correlation analysis. The
reliability and internal consistency of the SF-36 were
assessed via Cronbach’s α and the Nunnally criterion of
0.7 [11]. The responsiveness to change in the PCS and
MCS were assessed using effect sizes (ESs) and mini-
mum clinically important differences (MCIDs). The ES
was calculated by dividing the change in the score for
each measure by its baseline SD [12]. The ESs were
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large (≥0.8), according to Cohen’s classification [13]. The
MCID was defined as the smallest difference in a score that
the patients perceived as beneficial and that could mandate
a change in their management [14]. We used a distribution-
based method to calculate the MCID values for both QOL
instruments and applied the following formula: 1-SEM [a
change of 1 standard error of the mean (SEM)] = SD ×
√(1-α), where α is the Cronbach’s reliability coefficient
[15]. A change of 1 SEM was empirically demonstrated to
correspond to the MCID in a previous study using the SF-
36, which indicates that the 1-SEM criterion can be ap-
plied as a proxy for a clinically meaningful change. Values
less than p < 0.05 were considered statistically significant.
Results
Altogether, 142 patients with CSM who were treated by
the same group of spinal surgeons in our hospital from
February 2008 to November 2011 were enrolled in the
study. The group comprised 84 men and 58 women
whose ages ranged from 32 to 90 years (mean 60.0 years).
The mJOA follow-up rates were 93.0% (132/142) at
3 months after surgery, 84.5% (120/142) at 1 year after
surgery, and 99.3% (141/142) at the final follow-up more
than 2 years postoperatively. The SF-36 follow-up rates
were 88.7% (126/142) at 3 months, 84.5% (120/142) at
1 year, and 98.6% (140/142) at the final follow-up.
Regarding the current surgery index, 35.9% (51/142) of
the patients underwent anterior cervical discectomy with
fusion, 4.9% (7/142) underwent anterior cervical corpect-
omy with fusion, 7.9% (10/142) underwent artificial inter-
vertebral disc replacement, and 52.1% (74/142) underwent
laminoplasty. The mJOA scores are shown in Table 1.
SF-36 profile
The SF-36 reference values for a normal population were
adopted from the normal reference values of populationsTable 1 Demographics for patients with cervical spondylotic
myelopathy
Age(years) Mean = 60.0 Range = 32-90
Gender Male = 84 (39.8%) Female = 58 (60.2%)
Treatment Posterior Approach Laminoplasty 74








ACDF: anterior cervical discectomy with fusion; ACCF: anterior cervical
corpectomy with fusion; mJOA: modified Japanese Orthopaedic Association scores.
Results are the numbers of patients unless otherwise stated.in Hangzhou city on various subscales, including age and
sex. These values were identified in 2001 by the Zhejiang
University School of Medicine using the Chinese version
of the SF-36 to survey the QOL of 1688 residents of
Hangzhou. Prior to surgery, all patients exhibited varying
degrees of decline in all sections compared with the
normal population. Three sections (RP, SF, RE) exhib-
ited the most significant declines (Table 2). At 3 months
after surgery, only one section of the SF-36 (PF) had
significantly improved (p < 0.05). At 1 year after surgery,
five sections (PF, RP, SF, RE, MH) had significantly
improved (p < 0.05). At the final follow-up, the patients
exhibited significant improvements in four sections (PF,
RP, SF, RE) (p < 0.05). In terms of health transition, the
preoperative score of the patients was 4.09 ± 0.109. At
3 months, 1 year, and the final follow-up after posterior
cervical surgery, the scores were 2.62 ± 0.142, 2.51 ±
0.118, and 2.68 ± 0.133, respectively. The PCS peaked at
17.7 months and the MCS at 18.9 months (Figure 1).
Thus, during the postoperative follow-up at three time
points, all three PCS scores had significantly improved
compared with the preoperative score (p < 0.05). Al-
though all three MCS scores had increased compared
with the preoperative values, the differences were not
significant (p > 0.05).Psychometric evaluation
The Cronbach’s α coefficient of internal consistency was
used to estimate the reliability of the eight scales
(Table 3). In all cases, the value exceeded the minimum
standard of 0.70. Cronbach’s α ranged from 0.73 (for RE)
to 0.85 (for PF).
The ceiling and floor effects identified the percentage
of individual results that corresponded to the theoretical
maximum or minimum (Table 3). The prevalence of pa-
tients with a ceiling and floor effect for the SF-36 scales
ranged from 0 to 15.9%. The RE domain had the greatest
ceiling and floor effect values.
The ES for each domain and scale was calculated, with
larger values for the PF and RP subscales of the SF-36.
Bodily pain demonstrated the lowest responsiveness
(Table 3). ES, Cronbach’s α, and MCID of the PCS and
the MCS were also calculated (Table 4).Consistency between objective and subjective evaluations
At 3 months after surgery, improvements in neuro-
logical function (mJOA) were significantly associated
only with the PF and bodily pain of the patients (p < 0.05).
At 1 year after surgery, improvements in neurological
function correlated with four sections (PF, GH, SF, RE)
(p < 0.05). At the final follow-up, PF, VT, and RE exhib-
ited significant improvements in neurological function
(Table 5).
Table 2 Comparison of preoperative and postoperative SF-36 items with the normal population
Parameter PF RP BP GH VT SF RE MH
Normal men 81.6 ± 17.3 82.3 ± 32.2 81.8 ± 20.0 56.2 ± 20.1 55.0 ± 21.5 81.8 ± 17.6 87.1 ± 17.6 65.8 ± 17.6
CSM men
Preoperation {79) 54.9 ± 24.7 16.5 ± 25.6 48.7 ± 24.4 46.5 ± 21.4 51.1 ± 19.8 51.5 ± 19.8 26.0 ± 32.2 64.3 ± 20.7
3-Months postoperation (72) 71.5 ± 23.9 21.2 ± 31.6 54.3 ± 21.8 50.9 ± 21.8 52.9 ± 19.7 56.1 ± 27.1 42.5 ± 45.9 67.3 ± 20.2
1-Year postoperation (71) 78.5 ± 19.2 40.5 ± 36.2 55.0 ± 21.8 45.4 ± 20.2 53.0 ± 20.4 63.6 ± 24.4 52.9 ± 38.5 69.7 ± 19.8
Final follow-up (83) 77.4 ± 21.6 42.2 ± 40.2 55.5 ± 25.2 49.3 ± 21.9 52.1 ± 22.9 63.2 ± 25.8 54.5 ± 43.7 66.3 ± 20.8
Normal women 76.8 ± 18.9 77.6 ± 36.0 74.7 ± 25.5 50.9 ± 18.4 48.0 ± 18.8 83.2 ± 19.0 87.1 ± 35.8 65.8 ± 23.3
CSM women
Preoperation (53) 55.0 ± 20.7 20.6 ± 28.1 49.6 ± 21.6 45.8 ± 20.1 48.3 ± 22.3 50.3 ± 26.7 26.6 ± 29.8 60.6 ± 21.5
3-Months postoperation (54) 65.7 ± 21.1 17.6 ± 29.8 45.1 ± 17.4 47.1 ± 20.0 48.8 ± 20.2 54.2 ± 22.8 32.7 ± 39.7 66.7 ± 18.4
1-Year postoperation (49) 77.8 ± 19.3 37.8 ± 35.4 49.8 ± 17.9 43.6 ± 18.8 46.5 ± 20.1 61.2 ± 24.0 43.4 ± 38.5 64.6 ± 17.2
Final follow-up (57)) 76.7 ± 21.6 37.0 ± 36.3 46.0 ± 19.8 43.8 ± 18.9 45.1 ± 21.3 58.3 ± 26.5 49.4 ± 45.8 61.6 ± 20.1
PF: physical function; RP: role-physical; BP: bodily pain; GH: general health; VT: vitality; SF: social function; RE: role-emotional; MH: mental health.
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Many researchers have reported that surgical treatment
of CSM can achieve satisfactory mid-term or even long-
term results [16,17]. Previously, an evaluation of the
postoperative curative effects of the procedure was pri-
marily based on alleviation of neurological dysfunction
(such as that assessed by the mJOA) [18]. In recent
years, however, more attention has gradually been paid
to the subjective feelings of patients (assessed using SF-
36) [19]. However, a comprehensive clinical assessment
should consider both disease-specific and general health
evaluations [20]. Few studies have focused on SF-36 scores
after surgery for CSM patients or on their consistency
with the assessment of neurological function. In the
present study, we prospectively collected patient data and
retrospectively analyzed the follow-up data of 142 patients
with CSM who underwent surgical treatment. We then
calculated the responsiveness and statistically demon-
strated the reliability of the SF-36 in this cohort of ChineseFigure 1 Curves of changes in mJOAscore, PCSand MCS.patients. We subsequently explored the profiles of mid-
term health-related QOL outcome assessments after
surgery for CSM patients as well as the consistency of
these profiles with neurological function assessments
using a prospective cohort study.
The psychometric evaluation of the Chinese version of
the SF-36 indicated that it has acceptable metric charac-
teristics. Cronbach’s α coefficient value (all eight scales
were >0.7) indicated high internal consistency of the
scales. The prevalence of patients with a ceiling and
floor effect for the SF-36 scales was typically less than
15%, which is considered small [21]. The RE domain had
the highest ceiling and floor effect values, which is simi-
lar to the findings reported by Thakar et al. [22]. These
characteristics diminished the ability of the survey to dif-
ferentiate individuals according to their health status,
which was clearly apparent when the results were con-
verted to standardized or normalized values. The SF-36
was constructed to achieve the minimum standards of
Table 3 Responsiveness, reality, and ceiling and floor effects of SF-36 scales
QOL measures: SF-36 scales Lowest possible score (floor) (%) Highest possible score (ceiling) (%) Cronbach α ES
Physical function 4 (3.03) 1 (0.76) 0.85 0.91
Role-physical 13 (9.85) 3 (2.27) 0.83 0.93
Bodily pain 2 (1.51) 3 (2.27) 0.80 0.57
General health 0 1 (0.76) 0.81 0.79
Vitality 2 (1.51) 1 (0.76) 0.81 0.73
Social function 1 (0.76) 2 (1.51) 0.79 0.74
Role-emotional 21 (15.9) 7 (5.30) 0.73 0.82
Mental health 1 (0.76) 4 (3.03) 0.75 0.77
QOL: quality of life; ES: effect size.
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health areas. The ceiling and floor effect values for the
PCS and MCS were 0. Thus, the results of the present
study support the reliability and discriminative validity
of the SF-36. The eight scales of the SF-36 had medium
or large ES values according to Cohen’s classification,
with larger values observed for PF (ES 0.91) and RP (ES
0.93), indicating high responsiveness of the SF-36. The
MCIDs of the PCS and the MCS were 5.52 and 3.43,
respectively.
CSM has a significant impact on QOL. The SF-36
scores indicated that, compared with the normal popula-
tion, both male and female patients exhibited degrees of
decline in all sections, particularly in PF, SF, and RE. The
scores suggest that the impact of cervical myelopathy on
patient QOL is mainly reflected in such aspects as social
activities and the capacity to complete work. The health
changes of the patients compared with their preoperative
conditions (health transition 4.23 ± 0.692) clearly dem-
onstrated a significant impact on QOL.
The HTI scores of the patients at 3 months after sur-
gery, 1 year after surgery, and the final follow-up more
than 2 years after surgery were 2.14 ± 0.741, 2.41 ± 0.622,
and 2.62 ± 0.564, respectively, which demonstrates that
surgical treatment has a positive role in the subjective
evaluation of patients with CSM [23,24]. Al-Tamimi
et al. reported similar results in 2013 [25]. At 3 months
after surgery, the SF-36 scores of the patients exhibited
significant improvement in only one item (PF), whichTable 4 ES, Cronbach α, MCID, and ceiling and floor




Cronbach α 0.88 0.83
Lowest possible score (floor) 0 0
Highest possible score (ceiling) 0 0
ES: effect size; MCID: minimum clinically important difference; PCS: physical
component score; MCS: mental component score.was not consistent with the significantly improved
neurological function observed after surgery. A potential
explanation for this result might be that at 3 months
after surgery, despite improved neurological function
and somewhat improved sensory and motor functions
compared with the preoperative conditions, factors such
as postoperative wound pain and wound-related restric-
tions on activities prevented direct reflection of improved
neurological function in the patients [26-29]. As wounds
healed and the capacity and intent of the patients to par-
ticipate in social activities increased, the patients exhibited
significant improvements in PF, RP, SF, and emotional
function at the mid-term and long-term follow-up evalua-
tions compared with the preoperative conditions. As a
result, an improvement in neurological function could
play a meaningful role in the daily activities of the patients.
Prior to surgery, the patients might even have expected
improvements in these four aspects. Not all of the SF-36
scales had improved, however, which is inconsistent with
the results reported by Thakar [30].
At 3 months after surgery, the neurological improve-
ment mainly exhibited high correlations with the PF sec-
tion on the SF-36 scale of the subjective evaluation.
Patients considered that physical functions (e.g., walking
up and down stairs, bathing, getting dressed, completing
normal work) had improved with enhanced neurological
function. At the later recovery time points (e.g., 1 year
after surgery), the SF-36 scale sections that correlated
with improvements in the mJOA scores included both
physical and mental functions. At the final follow-up,
however, the mJOA score was more highly associated
with the mental function sections, indicating that im-
provements in neurological function would ultimately
lead to improved mental function in patients over a lon-
ger period of time.
Figure 1 shows that the mJOA scores, PCS, and MCS
reached their maximum values at 16.4, 17.7, and
18.92 months after surgery, respectively. The results re-
ported by Suzuki et al. in 2009 demonstrated that the
mJOA score peaked at 8.7 months after surgery and that
the recovery process could persist for up to 2 years [31].
Table 5 Correlations between mJOA scores and various SF-36 items
Parameter PF RP BP GH VT SF RE MH
CC (R) between preoperation and at 3 months after surgery (n = 116) 0.32* 0.04 0.20* 0.18 0.09 0.17 0.04 0.13
CC (R) between preoperation and at 1 year after surgery (n = 110) 0.39* 0.08 0.15 0.24* 0.13 0.22* 0.19* 0.08
CC (R) between preoperation and at final follow-up (n = 128) 0.38* 0.07 0.11 0.04 0.20* 0.16 0.20* 0.12
CC: correlation coefficient.
*p < 0.05.
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the mJOA score peaked at 16.4 months after surgery
and that further recovery could be expected up to
3 years postoperatively. Although the methods used in
this study and that of Suzuki et al. were different, the
significantly longer postoperative neurological recovery
process observed for our group of patients compared
with those assessed by Suzuki et al. might be a result of
the differences between the Japanese and Chinese popu-
lations or between postoperative rehabilitation therap-
ies. We believe that the data in the present study are
more suitable for Chinese populations and that they
provide useful information regarding the rehabilitation
process for CSM patients in China. To our knowledge,
there have been no reports regarding the time required
after surgery to attain the maximum recovery of the
PCS and MCS. The present study demonstrated the
recovery process for the PCS and MCS after cervical
surgery in patients with myelopathy. From another per-
spective, these results demonstrated that patients who
first benefited from improved neurological function
exhibited improvements in physiological function. Also,
the psychological function improved with the gradual
improvement in the physiological function. Similar to
the mJOA score, the PCS and MCS recovery processes
could be extended to the third year after surgery, and a
small number of patients achieved their best surgical
treatment results (1.77%) at 5 years postoperatively.
It is important to take note of the improvements in
neurological function that did not have a positive influ-
ence on the RE and MH, such as psychological influ-
ences that affect normal work, the need to reduce
normal workload or activities, and depression. Changing
the medical model from a biomedical one to a bio-
psycho-social structured model, and with the character-
istics of CSM, reveals that the mental health of patients
is of great importance.
Five patients (3.5%)—two with C5 palsy and three with
cerebrospinal fluid (CSF) leak—developed complications.
The development of C5 palsy negatively affects QOL re-
garding both the PCS and MCS. The impact is typically
temporary, and over the long term the QOL is similar in
patients who do and do not develop C5 palsy, which is
consistent with the findings of Miller et al. [32]. When a
CSF leak occurred, the leak site was dabbed with a cotton
pad and the dura tear then covered with gelatin foam andsealed with fibrin glue. After the procedure, a subcutane-
ous drain was placed, and the skin incision was loosely
approximated. The CSF leak resolved spontaneously
within 3–5 days postoperatively in all three patients and
did not affect the QOL of these patients, which is similar
to the findings reported by Terence et al. [33].
There are some potential limitations to this study. The
intervals between the follow-up time points were long,
which led to relatively large errors when determining the
times at which the objective and subjective rehabilitation
effects reached optimal levels. Also, it was a single-
center study with a mid-term follow-up analysis. Multi-
center and long-term follow-up studies are needed to
analyze further the subjective and objective postopera-
tive rehabilitation patterns of patients with CSM.
Conclusions
The SF-36 is a reliable instrument for evaluating patients
with CSM, demonstrating MCIDs of 5.52 for the PCS and
3.43 for the MCS. Compared with the normal population,
patients with CSM clearly have worse QOL prior to sur-
gery. Each domain of the SF-36 improved to some degree.
Early improvements in the objective evaluations based on
the mJOA scores indicated a high correlation with the PF
section of the SF-36 scale for the subjective evaluation.
With extended recovery, the sections of the SF-36 scale
that were correlated with improvements in the mJOA
scores encompassed both physical and mental functions.
Improvements in neurological function, however, were
primarily correlated with the mental function section.
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